This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Granulosa cell carcinoma of ovary
C3_OVARY_GRANULOSA
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleonly females |
293373 |
2. Check conditionsNone |
293373 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
101 |
4. Check minimum number of eventsNone |
101 |
5. Include endpointsNone |
101 |
6. Filter based on genotype QC (FinnGen only) |
101 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Granulosa cell carcinoma of ovary
based on the number of shared cases.
Similar with more cases:
- Granulosa cell carcinoma of ovary, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of ovary
- Malignant neoplasm of ovary, excluding all cancers (controls excluding all cancers)
- malignant neoplasm of female genital organs
- malignant neoplasm of female genital organs, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 101 | 101 | - |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | - |
| Median age at first event (years) | 55.36 | 55.36 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 96
- Matched controls
- 958
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8620/3-C56.9
ICD-O-3
Adult granulosa cell tumor of ovary of ovary
+∞
138.3
96
*
C56.92
ICD-10 Finland
Malignant ovarian tumor, sex chord stroma derived
+∞
111.2
84
*
D39.10
ICD-10 Finland
Tumor of uncertain or unknown nature in the ovary without histology
81.1
45.1
49
12
B01AB10
ATC
tinzaparin; parenteral
21.9
28.2
43
34
JAL31
NOMESCO Finland
Laparoscopic omentectomy
333.2
26.0
25
*
128
Kela drug reimbursment
Cancers of female genital organs
55.4
21.7
25
6
C56.91
ICD-10 Finland
Malignant granulosa cell tumor in ovary
+∞
20.5
19
*
LAF11
NOMESCO Finland
Laparoscopic bilateral salpingo-oophorectomy
13.7
19.8
36
40
JAL00
NOMESCO Finland
Biopsy of peritoneum
117.1
18.3
19
*
JN4BD
NOMESCO Finland
Extensive body CT
12.5
18.0
34
40
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
7.0
17.3
70
267
B01AB05
ATC
enoxaparin; parenteral
6.8
17.2
61
195
JAL30
NOMESCO Finland
Omentectomy
49.8
17.1
20
5
LAF01
NOMESCO Finland
Laparoscopic unilateral salpingo-oophorectomy
20.8
16.3
24
15
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
25.4
16.0
22
11
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
7.2
14.7
41
90
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
20.3
14.2
21
13
JAL01
NOMESCO Finland
Laparoscopic biopsy of peritoneum
87.6
14.0
15
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
14.0
13.4
23
21
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
9.2
12.9
28
41
WX402
NOMESCO Finland
General anaesthesia
6.2
11.9
36
85
C56.00
ICD-10 Finland
Malignant tumor of the ovary without histology
122.9
10.6
11
*
JAL20
NOMESCO Finland
Excision or destruction of lesion of peritoneum
122.9
10.6
11
*
LCD01
NOMESCO Finland
Total laparoscopic hysterectomy
11.5
10.3
19
20
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
12.7
10.3
18
17
LCD00
NOMESCO Finland
Hysterectomy
7.8
9.9
23
37
WX404
NOMESCO Finland
Intravenous generell anesthesy
4.6
9.8
40
129
LCD04
NOMESCO Finland
Laparoscopic hysterectomy
7.0
8.8
22
39
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
7.4
7.7
18
29
LAF16
NOMESCO Finland
Excision of uterus, adnexes and lymph nodes for treatment of ovarian cancer
86.5
7.5
8
*
JN4AD
NOMESCO Finland
Body CT examination
7.7
7.5
17
26
JAP00
NOMESCO Finland
Freeing of adhesions in the peritoneal cavity
24.5
6.8
9
*
H02AB02
ATC
dexamethasone; systemic
5.0
6.8
22
54
JEA00
NOMESCO Finland
Appendectomy
6.4
6.7
17
31
LC2DE
NOMESCO Finland
Demanding ultrsound examination of uterus, parametrium and lower part of abdomen with speciel methods
6.9
6.7
16
27
D39.13
ICD-10 Finland
Uncertain growth nature of the ovarian tumor, sex chord derived
+∞
6.3
6
*
WC125
NOMESCO Finland
Demanding cytostatic therapy of local tumor recidive
+∞
6.3
6
*
A04AA01
ATC
ondansetron; systemic, rectal
5.7
6.1
17
35
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
80
411
5.55
12.63
4.7
3.8
—
—
—
0
0
25
53
5.94
11.94
3.0
1.4
30.6
22.8
iu/l
0.61
20
48
31
92
4.42
9.88
1.3
4.8
7.4
6.7
ug/l
0.04
20
75
46
205
3.28
7.82
2.0
2.0
—
—
—
0
0
14
27
5.86
7.20
1.9
1.4
38.2
206.7
u/l
—
5
7
70
450
2.81
5.48
3.1
3.6
0.0
0.0
estimate
0.49
14
85
69
446
2.73
5.24
3.5
4.9
0.0
0.0
estimate
0.00
13
87
8
12
7.13
3.75
1.0
1.6
—
—
—
0
0
8
19
4.48
2.74
1.0
1.4
—
—
—
0
0
22
111
2.26
2.60
3.7
2.7
0.8
0.8
mmol/l
0.46
22
105
94
827
2.97
2.48
14.3
11.3
81.7
83.4
ml/min/173m2
0.36
84
654
7
19
3.88
2.19
2.0
2.7
144.9
177.2
%
—
7
19
15
71
2.31
2.04
1.7
2.7
56.7
69.2
ml/min/173m2
—
7
29
16
79
2.22
1.98
3.8
3.5
—
—
—
0
0
35
232
1.78
1.90
1.6
1.4
—
—
—
0
0
65
517
1.72
1.81
10.4
9.3
3.5
3.8
e9/l
0.93
60
464
27
397
0.56
1.75
2.3
2.2
81.2
79.1
nmol/l
0.12
27
349
8
31
2.71
1.70
15.5
8.1
1.3
1.3
%
—
8
31
96
881
2.81
1.63
17.3
12.7
139.9
139.9
mmol/l
0.01
96
851
32
216
1.70
1.61
2.1
2.7
0.4
0.4
e6/l
0.10
24
152
33
233
1.62
1.38
3.8
4.0
0.0
0.0
estimate
0.00
13
86
11
55
2.12
1.33
1.4
1.8
—
—
—
0
0
37
274
1.55
1.25
2.6
2.8
—
—
—
0
0
12
200
0.55
1.14
1.6
1.5
—
—
—
0
0
81
877
0.61
1.04
4.3
4.8
2.7
2.9
mmol/l
0.67
76
812
19
125
1.64
1.03
1.6
2.4
2.9
1.1
e6/l
0.72
11
65
93
866
1.93
1.03
12.8
12.1
26.5
19.9
mg/l
1.15
79
636
0
29
0.00
0.99
0.0
2.6
—
0.0
—
0
29
0
29
0.00
0.99
0.0
2.6
—
0.0
—
0
29
0
29
0.00
0.99
0.0
2.6
—
0.0
—
0
29
0
29
0.00
0.99
0.0
2.6
—
38.0
—
0
29
6
30
2.06
0.88
1.5
3.3
14.2
39.8
u/ml
—
6
30
7
121
0.55
0.84
1.6
1.7
—
—
—
0
0
52
439
1.38
0.83
3.3
3.6
0.0
0.0
estimate
0.00
14
87
6
33
1.87
0.80
3.2
2.5
50.1
44.8
%
—
6
33
81
866
0.67
0.75
3.9
4.3
4.8
4.9
mmol/l
0.21
76
810
26
331
0.71
0.74
1.5
1.9
85.5
102.3
pmol/l
0.95
11
151
5
25
2.05
0.74
1.0
1.3
—
—
—
0
0
5
25
2.05
0.74
1.0
1.4
—
—
—
0
0
9
57
1.63
0.73
2.6
3.1
6.5
5.8
kpa
—
9
57
7
43
1.67
0.68
3.3
1.3
—
—
—
0
0
75
808
0.72
0.66
4.4
5.2
39.7
39.1
mmol/mol
0.19
68
762
8
54
1.52
0.59
1.1
1.0
—
—
—
0
0
6
36
1.71
0.58
8.3
3.6
22.1
25.4
mmol/l
—
6
36
15
114
1.37
0.44
1.5
2.6
6.9
4.7
e6/l
—
7
55
7
102
0.66
0.42
3.1
1.7
—
—
—
0
0
5
33
1.54
0.42
2.6
2.8
—
—
—
0
0
5
33
1.54
0.42
3.6
2.2
1.2
1.2
%
—
5
33
0
15
0.00
0.41
0.0
1.6
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
40
351
1.23
0.41
3.6
3.6
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
6
44
1.39
0.35
1.2
1.7
—
—
—
0
0
57
612
0.84
0.32
3.1
3.1
—
—
—
0
0
82
848
0.82
0.25
3.9
4.4
5.7
5.8
mmol/l
0.30
76
781
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
6
47
1.29
0.21
1.3
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
22
196
1.16
0.18
3.0
2.9
964.8
732.0
ng/l
0.32
22
162
9
77
1.19
0.16
1.6
1.9
358.1
371.4
nmol/l
—
9
72
18
196
0.90
0.10
1.2
1.3
3.2
11.1
u/ml
—
8
84
19
199
0.94
0.03
1.3
1.3
15.0
28.9
iu/ml
—
7
74
28
288
0.96
0.02
2.9
3.4
12.2
21.6
ng/l
2.17
20
180
11
104
1.06
0.01
5.2
5.8
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
95.3
—
0
9
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
19.5
—
0
5
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
5.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_OVARY_GRANULOSA – Granulosa cell carcinoma of ovary
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).